Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Flat-coated retrievers set to benefit from new cancer research
Flat-coated retrievers are particularly susceptible to histiocytic sarcoma.

Simple blood test could allow for the early detection of the disease

One of the UK’s native gun dogs, the flat-coated retriever, is set to benefit from new research into a rare but aggressive form of cancer.


Research shows more than 50 per cent of flat-coated retrievers die of cancer and the breed is particularly susceptible to histiocytic sarcoma (HS) - a type of cancer found in multiple locations across the body. The outlook for the disease is extremely poor and, in most cases, terminal. 

Now scientists at the Animal Health Trust (AHT) and the University of Cambridge are set to carry out new research into the creation of a blood test for the early detection of HS in flat-coated retrievers. An early diagnosis would improve the chances of successful treatment and extend survival time.


Dr Anna Hollis, a cancer researcher at the AHT, said: “I have flat-coated retrievers and have lost one of them to histiocytic sarcoma - it is absolutely devastating. This research could make a significant difference, and that is a huge personal motivation for me."

In the study, researchers plan to confirm if there is a specific microRNA ‘signature’ that is unique to HS amongst tumours and tissue samples from flat-coated retrievers. MicroRNAs are often found in tumours and vary between different types of cancer.

If such a signature is identified, the project will investigate if measuring the levels of these microRNAs within a flat-coated retriever tissue sample can be used to identify a histiocytic sarcoma.

Should the team identify a microRNA ‘signature’ in histiocytic tumours, they will then seek additional funding to see if the same signature can be identified in the blood of affected dogs. If they find a microRNA signature, this could potentially be identified by a single blood test.


This would mean that a blood sample from a flat-coated retriever that was lame could be tested for the presence of HS-associated microRNAs - allowing for the disease to be detected at an earlier stage.

Dr Hollis continued: “Often lame dogs are rested and given pain relief before imaging is sought. Delayed diagnosis is a potential problem with histiocytic sarcoma given its aggressive nature and ability to spread rapidly to other locations within the body. 


"If we could identify affected dogs at an earlier stage, this may allow more successful treatment of the disease.”

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
Wales licenses Bluetongue vaccines for voluntary use

The Welsh government has approved three Bluetongue vaccines for emergency use in Wales.

From 1 March an online general licence will become available for the vaccines' use. They will then be obtainable on prescription and can be sold by veterinary practices.

After appropriate guidance, livestock keepers will be permitted to administer the vaccines themselves. The vaccines must be prescribed by a veterinary surgeon and detailed vaccination records must be kept for five years.

The decision comes as Bluetongue virus (BTV-3) continues to spread across England. The three vaccines are already licensed for use in England.

Richard Irvine, CVO for Wales, said: "This decision to licence these vaccines was informed by our recent risk assessment indicating that Wales is now at high risk of experiencing an incursion of Bluetongue this year.

"Our primary aim is to keep Bluetongue out of Wales through biosecurity, vigilance and safe sourcing of livestock."